Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 15/20 | 0.74 |
| ▸ | CTSB | P07858 | 3/20 | 0.74 |
| ▸ | CTSL | P07711 | 3/20 | 0.74 |
| ▸ | CTSK | P43235 | 2/20 | 0.74 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CTSH | P09668 | 1/20 | 0.74 |
| ▸ | CTSS | P25774 | 1/20 | 0.74 |
| ▸ | CTSC | P53634 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | CTSG | P08311 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11188762 | 0.99 | CAPN1 (0.72) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL11184932 | 0.99 | CAPN1 (0.72) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL30643189 | 0.93 | CAPN1 (0.69) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL212151 | 0.89 | CAPN1 (0.60) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL23132676 | 0.88 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL7087294 | 0.88 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL4740187 | 0.88 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL13283063 | 0.88 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL13523481 | 0.88 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL16452857 | 0.88 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-4682264-A1 | ASSAY SYSTEM FOR DEVELOPING HONEYBEE ANTIVIRAL AGENT USING INHIBITION OF VIRUS-DERIVED PROTEASE AS INDICATOR | Toyama Prefectural University (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3655015-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | UNIV COLORADO REGENTS (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | UNIV CHICAGO (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | TSINGHUA UNIVERSITY (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4208174-A2 | NUCLEIC ACID-DERIVATIZED THERAPEUTICS | The University of Chicago (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116367849-A | Therapeutic agent derived from nucleic acid | 芝加哥大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-11452709-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-09-27 | — | — | US | disclosed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-4474800-A | PROTEASE INHIBITORS, MUSCULAR DYSTROPHY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1984-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | CTSE, CTSB, ATG4B | CAPN1 596/4885CTSB 2/4885CTSL 26/4885 |
| US-11452709-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | CTSE, CTSB, ATG4B | CAPN1 596/4885CTSB 2/4885CTSL 26/4885 |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | CTSE, CTSB, ATG4B | CAPN1 596/4885CTSB 2/4885CTSL 26/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | CAPN1 226/4885CTSB 2/4885CTSL 13/4885 |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | NSUN2, NSUN3, POLRMT | CAPN1 632/4885CTSB 502/4885CTSL 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.